July 21st, 2026
Twenty years ago or so, researchers were investigating the possibility of building therapies based on upregulation of TFAM expression to improve mitochondrial function in aged tissues. While some initial results were promising, as it turned out the mitochondrial biochemistry of TFAM is complicated and too much is as bad as too little. This makes it a poor target for gene therapy, and a challenging target for small molecules. The field moved on to easier possibilities, as often happens. Still, nothing ever really stops entirely in the life sciences. Here find a review of the present state of knowledge regarding TFAM, and some speculation as to what future therapies might look like.
Mitochondrial transcription factor A (TFAM) is a nuclear-encoded mitochondrial protein that directly binds mitochondrial DNA (mtDNA) and contributes to mitochondrial genome maintenance. Beyond its established roles in mitochondrial transcription, mtDNA packaging, nucleoid organization, replication support, and copy number control, TFAM is increasingly recognized as a potential regulator of aging-related mitochondrial stress responses. Because mtDNA instability, respiratory dysfunction, reactive oxygen species imbalance, impaired autophagy, cellular senescence, and chronic inflammation are closely interconnected during aging, TFAM may occupy a proximal position linking mitochondrial genome homeostasis to broader aging biology.
